The Mesoblast limited (ASX: MSB) share price has continued its incredible run today, surging another 25.5% to $2.76, although it did trade for as much as $3.03 earlier in the session. Shares traded for as little as $1.14 on 12 February, representing a gain of 142% in less than three weeks at its current price.

Source: ASX; six-month share price chart for Mesoblast

Source: ASX; six-month share price chart for Mesoblast

Mesoblast operates in the biotechnology sector and is focused on developing products for regenerative medicine.

In regards to today’s sharp rise in the company’s share price, there were no market releases issued by the group that would explain the rise – at least not as far as I could tell – but the gains could be attributed to recent developments with the group.

Indeed, Mesoblast recently announced positive results for its Phase 2 rheumatoid arthritis trials – a market it believes could be worth $18.4 billion by 2024 – while it also showed that its stem cell treatment was helping children suffering steroid-refractory acute Graft Versus Host Disease (aGVHD) survive bone marrow transplants.

Of course, there are plenty of risks associated with owning shares in biotechnology companies, and they can be extremely volatile even at the best of times; just ask shareholders of Orthocell Ltd (ASX: OCC) or even Sirtex Medical Limited (ASX: SRX).

For starters, the company generates very little revenue yet burns through cash to fund research and development. It has recently cut back on spending which is great, although there is still a chance further capital raisings will be required in the future.

Still, if everything goes according to plan, Mesoblast’s shares could be worth a lot more in the future than they are today. It’s a potentially high-risk/high-reward play and should only be considered by investors with the ability to stomach violent swings in share prices, and those with the patience to stay invested for the long term.

Although the shares have gained 142% in less than three weeks, they’re still sitting nearly 34% below their 52-week high (again highlighting the volatile nature of the shares).

Our BEST stock idea for 2016 - FREE!

Our top analysts have recently selected their TOP stock idea for 2016, and with share prices falling, it could be the BEST time to buy! This relatively unknown technology share is growing rapidly and offers a fat, fully franked dividend! Best of all: their top stock idea for 2016 is yours FREE! Just click here, enter your email address and claim your free report - no payment or credit card required!

HOT OFF THE PRESSES: Motley Fool’s #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our https://www.fool.com.au/financial-services-guide">Financial Services Guide (FSG) for more information.

Motley Fool contributor Ryan Newman has no position in any stocks mentioned. Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below. You can follow Ryan on Twitter @ASXvalueinvest.

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.